Ophthalmology

More than 6.8 million people suffer from vision loss in one eye and roughly one million in both eyes because of corneal diseases. For common people, the opaque cornea is just a medical…

Exton, Pennsylvania, July 28, 2023 (GLOBE NEWSWIRE) -- For many who have been following the retina market, the news about the emerging safety signal associated with Apellis’ Syfovre in…

BERN, Switzerland and BOSTON, July 25, 2023 (GLOBE NEWSWIRE) -- RetinAI Medical AG (“RetinAI”), a leader in clinical and imaging data management software and advanced analytics using…

ALPHARETTA, Ga., July 11, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye…

- XIPERE® is referred to as Arcatus (ARVN001) by Arctic Vision – ALPHARETTA, Ga., July 10, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical…

Pune, India, July 06, 2023 (GLOBE NEWSWIRE) -- The Insight Partners adds "Biomaterials Market Size, Share & Revenue Forecasts to 2028 - Covid-19 Impact and Global Analysis - by Type…

Wilmington, Delaware, United States, July 04, 2023 (GLOBE NEWSWIRE) -- The global pericardial patches market is anticipated to grow at a 6.8% CAGR from 2023 to 2031. A market valuation of…

Exton, Pennsylvania, June 28, 2023 (GLOBE NEWSWIRE) -- With the U.S. FDA approval of Apellis’ Syfovre (pegcetacoplan) on February 17th, 2023 for the treatment of geographic atrophy (GA),…

- First-in-human clinical trial of MyopiaX®, the first therapeutic approach in juvenile myopia to target the dopamine pathway digitally- Enrollment ongoing in Germany, Spain, the…

- Primer ensayo clínico en humanos de MyopiaX® , el primer enfoque terapéutico para la miopía juvenil dirigido digitalmente a la vía dopaminérgica.- Inscripción en curso en Alemania,…